Deazaflavin compounds and methods of use thereof
View Patent ↗The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.
1. A method of treating cancer comprising administering to a subject suffering from cancer a compound of the following Formula IV
wherein R 4 is selected from the group consisting of amino, halogen, hydroxy, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, or mono or di(C 1-6 alkyl)amino; and pharmaceutically acceptable salts thereof
and wherein the cells of said cancer retain a wild type p53 gene.
2. The method of claim 1 wherein R 4 is amino.
3. The method of claim 1 wherein R 4 is halogen.
4. The method of claim 1 wherein R 4 is hydroxyl.
5. The method of claim 1 wherein R 4 is C 2-6 alkenyl or C 2-6 alkynyl.
6. The method of claim 1 wherein R 4 is C 1-6 alkoxy.
7. The method of claim 1 wherein R 4 is mono or di(C 1-6 alkyl)amino.
8. The method of claim 1 wherein R 4 is selected from the group consisting of a chloro or fluoro group, and R 4 is attached to the 3 or 4 position of the phenyl ring.
9. The method of claim 1 wherein R 4 is chloro and is attached to the 3 or 4 position of the phenyl ring.
10. The method of claim 1 wherein R 4 is fluoro and is attached to the 3 or 4 position of the phenyl ring.
11. The method of claim 1 wherein R 4 is methyl and is attached to the 3 or 4 position of the phenyl ring.
12. The method of claim 1 wherein the compound is selected from the group consisting of 10-(3-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione, and 10-(4-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione; and pharmaceutically acceptable salts thereof.
13. The method of claim 1 wherein the subject has a solid tumor.
14. The method of claim 1 wherein the subject has a disseminated cancer.
15. The method of claim 1 wherein the patient is a mammal.
16. The method of claim 1 wherein the patient is a primate or human.
17. A method of treating cancer comprising:
administering a compound of the following Formula IV to a subject suffering from cancer of the colon, prostate, breast or skin:
wherein R 4 is selected from the group consisting of amino, halogen, hydroxy, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, or mono or di(C 1-6 alkyl)amino; and pharmaceutically acceptable salts thereof
and wherein the cells of said cancer retain a wild type p53 gene.
18. The method of claim 17 wherein R 4 is amino.
19. The method of claim 17 wherein R 4 is halogen.
20. The method of claim 17 wherein R 4 is hydroxyl.
21. The method of claim 17 wherein the compound is selected from the group consisting of 10-(3-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione, and 10-(4-chloro-phenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione; and pharmaceutically acceptable salts thereof.
22. The method of claim 17 wherein the subject is suffering from breast cancer.